Sarah Kilyanek

Lead Upstream & Business development strategy, research & forecasting for ST Europe

· Upstream Portfolio Strategy: Spearhead the formulation and execution of the upstream portfolio strategy for Europe, driving new product development together with the global upstream team.

· Business Development: Establish and nurture relationships with external companies and internal stakeholders to set business development strategy and to identify and qualify opportunities.

· Cross-functional collaborative leadership: Partner with European sales colleagues, global upstream marketing, BD and R&D colleagues to provide European input, ensuring alignment with overarching strategic goals.

· Strategic Launch Initiatives: Lead the development and Q4 2023 launch of Neptune S in both a new market (GI) and an existing market with Neptune 3

· Innovative Contract Development: Collaborated with Flex, Legal, and Finance partners to develop a new Flex Finance contract tailored to meet the unique needs of the GI market.

Drove acquisitions $200M OI business and $60M ST business

· Acquisition Success: Completed due diligence and integration with cross-functional teams for SafeAir European acquisition, Invuity, Zip Medical, and Gauss Surgical global acquisitions.

· Future Market Analysis: Analyzed and identified future markets and businesses for investment, through direct VoC, primary market research, secondary data analysis and insights from commercial, R&D and RA colleagues.

· Strategic Alignment: Collaborated globally to ensuring alignment with business strategy and objectives.

· Target Engagement and Financial Analysis: Established relationships with target companies, conducted financial forecasting, competitive evaluations, and market research to present compelling business cases and gain buy-in.

· Senior Management Buy-in: Successfully pitched acquisition targets to European senior management and corporate business development teams.

· People Leadership: 12 direct reports over 3 years. Designed and led a European marketing intern program, overseeing 10 interns, Education and MarComms.

Led European OI marketing team of 15 RHQ and country marketers during Covid 19 pandemic, concurrent with BD responsibilities for OI and ST

· Budget Achievement & Launches: Successfully oversaw the launches of new products (T7, System 9, and power accessories) with an outstanding 130% budget achievement.

· Team Wellbeing and Development: Led business strategy, team wellbeing, and career development during the unprecedented challenges in the industry, embracing remote work dynamics.

· Q12 Improvement: Significantly enhanced Q12 scores and day-to-day engagement amidst the global pandemic by swiftly building relationships, understanding team dynamics, and fostering trust, accountability, open communication, and experimentation.

· Change Management: Created focus, managed change, and fostered creativity in activities, spending, and time-management to maximize sales and team productivity in a new remote environment.

· Talent Management and Organizational Design: Designed new roles, conducted promotions, transfers, and terminations, contributing to a strategic alignment of talent with organizational goals.

• Led European OI portfolio for Personal Protection Equipment (PPE) and orthopaedic disposables. Responsible for marketing strategy, analytics and research, tactical design, and salesforce alignment for 5 brands

Pradaxa® ($1B) global marketing lead for launch of Deep Vein Thrombosis and Pulmonary Embolism indication.

Led global strategy from pre-regulatory filing through launch. Built internal commitment and alignment with corporate senior management, cross-functional brand teams and country marketing and leadership.

§ Led global strategic planning under short deadlines, including forecasting, physician primary market research, promotional materials, and external expert and communications plans.

§ Rapidly built strong working relationships with Regulatory, Medical and Market Access teams through shared accountability, open communication and actively soliciting team input.

· Led launch readiness reviews for 13 global markets, including USA, Europe and Emerging markets

· Achieved 100% regulatory approval (original internal expectations